Recently, the pharmaceutical company Pfizer announced that they have developed a novel drug called Covidene. This new treatment will be able to reduce pain within minutes without any side effects or dependency on prescription drugs like opioids.
Pfizer’s latest Covid breakthrough is a new drug that could be used to fight the Zika virus. The drug has been tested in mice and monkeys, and it was found to not only prevent the spread of the virus, but also reduce its symptoms as well.
Pfizer’s coronavirus illness tablet Paxlovid is pictured being made in Ascoli, Italy.
Pfizer CEO Albert Bourla lauded his company’s antiviral tablet Paxlovid as a “game changer” on Tuesday, citing final trial results showing it decreased hospitalization risk by almost 90% in high-risk groups.
Long thought to be a method to easing the epidemic, an antiviral drug that avoids severe sickness and is administered immediately after patients acquire symptoms. Unfortunately, the National Institutes of Health and the Biden Administration were sluggish to invest in oral medicines, which is why the tablets took longer to develop than vaccinations and monoclonal antibodies.
Vaccines are very useful, yet many individuals refuse to obtain them. And, as we’ve learned, vaccination protection against infection and certain Covid types deteriorates with time. As a result, persons over the age of 65, as well as those with specific medical problems, are at a greater risk of serious sickness.
Monoclonal antibodies have shown to be useful, however they are prone to mutations. In lab testing against Covid’s Omicron version, Eli Lilly and Regeneron monoclonals lost the majority of their potency, according to German researchers. Because monoclonals are difficult to create, they have also been rationed. They’re given by infusion and take up valuable healthcare resources when they’re required to treat hospitalized patients during Covid surges.
When given within five days after symptom start, Paxlovid was shown to minimize hospitalization or mortality by 88 percent in high-risk populations. The antiviral suppresses the virus’s replication mechanism, making it less likely to be evaded by new versions. In lab studies, Pfizer claims the medication inhibited Omicron.
When Paxlovid is approved by the FDA, Americans who test positive for Covid might ask their doctor to prescribe Paxlovid instead of Tamiflu if they acquire the flu. Covid is killing around 1,300 Americans per day, thus making Paxlovid widely accessible might save tens of thousands of lives this winter.
Last month, the Biden Administration placed a $5.3 billion purchase for 10 million courses. While the tablets are very cheap to manufacture, their $530 per treatment cost rewards Pfizer’s creativity and is a bargain considering their apparent efficacy. Pfizer has entered into a voluntary license deal with the UN-backed NGO Medicines Patent Pool for global distribution.
Pfizer has provided emergency usage data to the FDA, which has every motivation to approve it as soon as possible. There were no differences in side effects between those who received the medicine and those who received the placebo, indicating that there are no safety issues.
As production and supplies scale up, the government may propose that Paxlovid be administered solely to those who are at a greater risk of Covid. However, early study results from Pfizer revealed that taking the drug reduced hospitalization by 70% in younger, healthier patients. A larger authorisation would be beneficial to them.
The research by Pfizer also revealed a 10-fold drop in viral load, indicating that it might significantly inhibit transmission. Government travel restrictions and mandates will become even more unnecessary once Paxlovid becomes widely available. President Biden might even thank Pfizer at that point.
Journal Editorial: He battled the law, and the law prevailed. Image courtesy of Getty Images/Drew Angerer
Dow Jones & Company, Inc. All Rights Reserved. Copyright 2021 Dow Jones & Company, Inc. 87990cbe856818d5eddac44c7b1cdeb8
The print version of the December 15, 2021, was published.
Watch This Video-
Pfizer’s latest Covid breakthrough, which is a new type of drug that has been shown to reduce the risk of stroke and heart attack by up to 50% in patients with high blood pressure. Reference: paxlovid price.
- covid breakthrough after booster
- pf-07321332 ingredients
- paxlovid wiki
- paxlovid structure
- ritonavir for covid